Abstract
Background
Although some glycolytic intermediates have been shown to modulate several cell type formation and activation, the functional role of fructose 1,6-bisphosphate (FBP) on osteoclastogenesis is still unknown.
Methods
Osteoclastogenesis was evaluated on bone marrow preosteoclasts cultured with M-CSF − 30 ng/ml, RANKL − 10 ng/ml, and two concentrations of FBP (100 and 300 µM). TRAP-positive stained cells were counted, and osteoclastogenic marker genes expression were evaluated by qPCR. Osteoclasts resorption capacity was evaluated by the expression of specific enzymes and capacity to resorb a mineralized matrix. The NF-κB activation was detected using RAW 264.7, stably expressing luciferase on the NF-κB responsive promoter.
Results
We show that FBP, the product of the first stage of glycolysis, inhibited RANKL-induced osteoclasts differentiation and TRAP activity. The treatment of preosteoclasts with FBP attenuated osteoclast fusion and formation, without affecting cell viability. Moreover, the inhibition of several osteoclastogenic marker genes expression (TRAP, OSCAR, DC-STAMP, Integrin αv, NFATc1) by FBP correlates with a reduction of mineralized matrix resorption capacity. The mechanism underlying FBP-inhibition of osteoclastogenesis involves NF-κB/NFATc1 signaling pathway inhibition.
Conclusion
Altogether these data show a protective role of a natural glycolytic intermediate in bone homeostasis that may have therapeutic benefit for osteolytic diseases.
Similar content being viewed by others
References
Alford AI, Kozloff KM, Hankenson KD. Extracellular matrix networks in bone remodeling. Int J Biochem Cell Biol. 2015;65:20–31.
Adamopoulos IE, Mellins ED. Alternative pathways of osteoclastogenesis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11:189–94.
Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):493–514.
Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. Journal of Bone Metabolism. 2014;21:233–41.
Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3:889–901.
Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007;40:251–64.
Kim JM, Jeong D, Kang HK, Jung SY, et al. Osteoclast precursors display dynamic metabolic shifts toward accelerated glucose metabolism at an early stage of RANKL-stimulated osteoclast differentiation. Cell Physiol Biochem. 2007;20:935–46.
Lee YS, Kim YS, Lee SY, Kim GH, Kim BJ, Lee SH, et al. AMP-kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone. 2010;47:926–37.
Fong JE, Le Nihouannen D, Tiedemann K, Sadvakassova G, Barralet JE, Komarova SV. Moderate excess of pyruvate augments osteoclastogenesis. Biol Open. 2013;22(2(4):387–95.
Williams JP, Blair HC, McDonald JM, et al. Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun. 1997;235:646–51.
Ahn H, Lee K, Kim JM, Kwon SH, Lee SH, Lee SY, Jeong D. Accelerated lactate dehydrogenase activity potentiates osteoclastogenesis via NFATc1 signaling. PLoS One. 2016;11:e0153886.
Indo Y, Takeshita S, Ishii KA, Hoshii T, Aburatani H, Hirao A, Ikeda K. Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res. 2013;28:2392–9.
Jones W, Bianchi K. Aerobic glycolysis: beyond proliferation. Front Immunol. 2015;15:6:227.
Cohen JE, Atluri P, Taylor MD, Grand TJ, Liao GP, Panlilio CM, et al. Fructose 1,6-diphosphate administration attenuates post-ischemic ventricular dysfunction. Heart Lung Circ. 2006;15:119–23.
Ahn SM, Hwang JS, Lee SH. Fructose 1,6-diphosphate alleviates UV-induced oxidative skin damage in hairless mice. Biol Pharm Bull. 2007;30:692–7.
Xu K, Stringer JL. Pharmacokinetics of fructose-1,6-diphosphate after intraperitoneal and oral administration to adult rats. Pharmacol Res. 2008;57:234–8.
Veras FP, Peres RS, Saraiva AL, Pinto LG, Louzada-Junior P, Cunha TM, et al. Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating anti-inflammatory adenosinergic pathway. Scientific Reports. 2015;5:15171.
Ma B, Zhang Q, Wu D, Wang YL, Hu YY, Cheng YP, Yang ZD, Zheng YY, Ying HJ. Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta Pharmacol Sin. 2012;33:479–89.
Bordignon Nunes F, Meier Graziottin C, Alves Filho JC, Lunardelli A, Caberlon E, Peres A, Rodrigues De Oliveira J. Immunomodulatory effect of fructose-1,6-bisphosphate on T-lymphocytes. Int Immunopharmacol. 2003;3:267–72.
Shinohara M, Takayanagi H. Analysis of NFATc1-centered transcription factor regulatory networks in osteoclast formation. Methods Mol Biol. 2014;1164:171–6.
Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res. 2007;313:168–78.
Blair HC, Teitelbaum SL, Grosso LE, et al. Extracellular-matrix degradation at acid pH. Avian osteoclast acid collagenase isolation and characterization. Biochem J. 1993;290(Pt 3):873–84.
Boyce BF, Yamashita T, Yao Z, Zhang Q, Li F, Xing L. Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner Metab. 2005;23:11–15.
Yu M, Qi X, Moreno JL, Farber DL, Keegan AD. NF-κB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-κB pathways. J Immunol. 2011;187:1797–806.
Acknowledgements
The author’s thanks Mayara Santos Gomes for her technical assistance. This study was supported by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP grant No. 2015/09034-0; 2013/08216-2) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq-130230/2016-2 scholarship to LWB).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Additional information
Responsible Editor: Jason J. McDougall.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wilches-Buitrago, L., Viacava, P., Cunha, F.Q. et al. Fructose 1,6-bisphosphate inhibits osteoclastogenesis by attenuating RANKL-induced NF-κB/NFATc-1. Inflamm. Res. 68, 415–421 (2019). https://doi.org/10.1007/s00011-019-01228-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-019-01228-w